Clinical study of enzalutamide on castration resistant prostate cancer

Clinical study of enzalutamide on castration resistant prostate cancer - Enzalumide on CRPC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014702

Enrollment

100

Registered

2014-07-31

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration resistant prostate cancer

Interventions

Enzalutamide

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1 male, age >= 20 years old 2 hitologically proven prostate cancer 3 castrated state 4 castration resistant prostate cancer 5 PS 0 -2 6 radiographical metastasis site at diagnosis or teatment periods 7 obtain by written consent

Exclusion criteria

Exclusion criteria: 1 Epileptic state patients 2 Brain damage, apoplexy, brain metastatis, active epidural metastatis of cranium 3 Hypersensitivity to enzalutamide or its component 4 Severe liver dysfunction 5 Impropriate state judged by charged doctor

Design outcomes

Primary

Measure	Time frame
PSA response rate, 50% and 90%	—

Secondary

Measure	Time frame
Overall survival rate, radiographical progression free survival rate, progression free survival rate, QOL evaluation, serum levels of hormones and prognosis	—

Countries

Japan

Contacts

Public ContactHidekazu Koike

Gunma University Graduate School of Medicine Department of Urology

hkoike@gunma-u.ac.jlp207-220-8303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026